Skip to main content
. Author manuscript; available in PMC: 2017 Apr 5.
Published in final edited form as: Cell Rep. 2016 Mar 24;15(1):19–26. doi: 10.1016/j.celrep.2016.03.008

Figure 3. Myeloid JNK-deficiency suppresses the development of fulminant hepatitis.

Figure 3

(A) Mice (ØWT and ØKO) were treated with PBS or LPS/GalN (6 h). Representative images of the dissected liver (scale bar, 5 mm) and hematoxylin & eosin-stained liver sections are presented (upper panels). Apoptotic cells in the liver sections were examined by TUNEL assay (lower panels). Scale bars, 100 μm.

(B) The accumulation of hepatic aminotransferases (ALT and AST) in the blood of ØWT and ØKO mice was measured (mean ± SEM; n = 10, except ALT at 6 h, n = 9). Statistically significant differences between LPS/GalN-treated ØWT and ØKO mice are indicated (**, p<0.01).

(C) Liver extracts prepared from mice treated with PBS or LPS/GalN (6 h) were examined by immunoblot analysis using antibodies to α-Tubulin, Bad, Caspase 3, cleaved Caspase 3, PARP and cleaved PARP.

(D) Kaplan-Meier analysis of survival following treatment of ØWT and ØKO mice with LPS/GalN (n = 15). See also Figure S3.